Internet searches can identify drug safety issues well ahead of public alerts

The authors base their findings on an analysis of the anonymised search logs of millions of US web users, who agreed to install a browser add-on and share their online searches with Microsoft throughout 2010. The researchers developed automated tools to analyse the queries of people who searched for information on the antidepressant (paroxetine) and a cholesterol lowering drug (pravastatin), using the search engines Google, Bing and Yahoo.

In 2010, it was not yet public knowledge that taking both these two drugs caused high blood sugar (hyperglycaemia), but the authors later extracted this information by mining the US drugs regulator's medicines side effect reporting system (AERS) and confirming the finding in a separate laboratory study.

In the web log study, the authors looked at whether people who had searched online for either one of the drugs separately, or for both of them, would also search with queries containing terms associated with the symptoms of high blood sugar.

In all, they analysed 82 million drug, symptom, and condition queries from among 6 million web users.

They found that online searches for information on prescription drugs was common, with more than one in 250 people looking up at least one of the 100 top selling drugs in the US, including paroxetine and pravastatin.

For people who searched online for both drugs during the 12 month period, queries were made on the same day in almost a third (29.61%) of searches, while four out of 10 were in the same week. Six out of 10 were made within the same month.

During the study period, those people who looked up both drugs online were almost twice as likely to search for terms associated with high blood sugar as were those who looked up the drugs separately.

One in 10 of those looking up both drugs did this, compared with around one in 20 of those looking up each drug separately. Just 0.3% of all users searched for one or more terms associated with high blood sugar over the 12 months.

These differences in search patterns were evident across the whole period of the study, and were not influenced by public information as the discovery of the interaction between this particular pair of drugs was only made in 2011.

Analysis of other 31 drug pair interactions associated with high blood sugar also indicated similar patterns, suggesting that the value of log analysis is not just confined to paroxetine and pravastatin.

"There is a potential public health benefit in listening to such signals, and integrating them with other sources of information," write the authors. "We see a potentially valuable signal, even though search logs are unstructured, not necessarily related to health, and can include any words entered by users," they add.

And they conclude: "We believe that patient search behaviour directly captures aspects of patients' concerns about sensed [symptoms] and can complement more traditional sources of data for pharmacovigilance [drug safety monitoring]."

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]